MediciNova completes double-blind phase of 234-patient Phase 2b/3 ALS trial
AI Summary- MediciNova completed the double-blind portion of its COMBAT-ALS trial evaluating MN-166 in ALS.
- 234 participants were randomized across clinical sites in the United States and Canada.
- MediciNova expects double-blind topline results by the end of 2026.